This story is part of Forbes’ coverage of Korea’s Richest 2026. See the full list here.

In January, Sam Chun Dang Pharm struck potential gold in its efforts to develop a pill version of Denmark-based Novo Nordisk’s blockbuster weight-loss injectable Wegovy. It signed an agreement, the terms of which were not publicly disclosed, with Japan’s Daiichi Sankyo to jointly develop and sell the slimming medication, which uses Sam Chun Dang’s proprietary S-Pass technology to turn injectable medicines into easy-to-take pills.

The Korean company’s shares rocketed following the announcement, catapulting its chairman, Yoon Dae-in, onto the ranks of Korea’s 50 Richest at No. 10 with a $5.9 billion fortune. (Its stock fell after net worths were locked in when the stock exchange regulator issued a notice to Sam Chun Dang Pharm for inadequate........

© Forbes